Impact of surgical approach and resection technique on the risk of Trifecta Failure after partial nephrectomy for highly complex renal masses
Por:
Campi R., Di Maida F., Lane B.R., De Cobelli O., Sanguedolce F., Hatzichristodoulou G., Antonelli A., Noyes S., Mari A., Grosso A.A., Rodriguez-Faba O., Keeley F.X., Langenhuijsen J., Musi G., Klatte T., Roscigno M., Akdogan B., Furlan M., Karakoyunlu N., Marszalek M., Capitanio U., Volpe A., Brookman-May S., Gschwend J.E., Smaldone M.C., Uzzo R.G., Carini M., Kutikov A., Minervini A., Members of the SIB International Consortium
Publicada:
1 mar 2022
Ahead of Print:
1 mar 2022
Resumen:
Introduction: We aimed to compare the outcomes of open vs robotic partial nephrectomy (PN), focusing on predictors of Trifecta failure in patients with highly complex renal masses. Patients and methods: We queried the prospectively collected database from the SIB International Consortium, including 507 consecutive patients with cT1-2N0M0 renal masses treated at 16 high-volume referral centres, to select those with highly complex (PADUA score >10) tumors undergoing PN. RT was classified as enucleation, enucleoresection or resection according to the SIB score. Trifecta was defined as achievement of negative surgical margins, no acute kidney injury and no Clavien-Dindo grade >2 postoperative surgical complications. Multivariable logistic regression analysis was used to assess independent predictors of Trifecta failure.
Filiaciones:
Campi R.:
Department of Urology, University of Florence, Florence, Italy, Department of Experimental and Clinical Medicine, University of Florence, Florence, Italy
Di Maida F.:
Department of Urology, University of Florence, Florence, Italy, Department of Experimental and Clinical Medicine, University of Florence, Florence, Italy
Lane B.R.:
Department of Urology, Spectrum Health Medical Group, Grand Rapids, MI, United States
De Cobelli O.:
Department of Urology, European Institute of Oncology (IEO), University of Milan, Milan, Italy
Sanguedolce F.:
Bristol Urological Institute, Southmead Hospital, Bristol, United Kingdom
Uro-oncology Unit, Fundació Puigvert, Barcelona, Spain
Hatzichristodoulou G.:
Department of Urology, Technical University of Munich, Rechts der Isar University Hospital, Munich, Germany
Department of Urology, Martha-Maria Hospital Nuremberg, Germany
Antonelli A.:
Department of Urology, University of Brescia, Brescia, Italy
Department of Urology, University of Verona, Azienda Ospedaliera Universitaria Integrata Verona, Verona, Italy
Noyes S.:
Department of Urology, Spectrum Health Medical Group, Grand Rapids, MI, United States
Mari A.:
Department of Urology, University of Florence, Florence, Italy, Department of Experimental and Clinical Medicine, University of Florence, Florence, Italy
Grosso A.A.:
Department of Urology, University of Florence, Florence, Italy, Department of Experimental and Clinical Medicine, University of Florence, Florence, Italy
Rodriguez-Faba O.:
Uro-oncology Unit, Fundació Puigvert, Barcelona, Spain
Keeley F.X.:
Bristol Urological Institute, Southmead Hospital, Bristol, United Kingdom
Langenhuijsen J.:
Department of Urology, Radboud University Nijmegen Medical Centre, Nijmegen, Netherlands
Musi G.:
Department of Urology, European Institute of Oncology (IEO), University of Milan, Milan, Italy
Klatte T.:
Department of Urology, Royal Bournemouth Hospital, Bournemouth, United Kingdom
Department of Urology, Medical University of Vienna, Vienna, Austria
Roscigno M.:
Department of Urology, ASST Papa Giovanni XXIII, Bergamo, Italy
Akdogan B.:
Department of Urology, Hacettepe University, School of Medicine, Ankara, Turkey
Furlan M.:
Department of Urology, University of Brescia, Brescia, Italy
Karakoyunlu N.:
Department of Urology, Diskapi Yildirim Beyazit Training and Research Hospital, Ankara, Turkey
Marszalek M.:
Department of Urology and Andrology, Donauspital, Austria
Department of Urology, Graz Medical University, Graz, Austria
Capitanio U.:
Unit of Urology, Division of Experimental Oncology, Urological Research Institute (URI), IRCCS Ospedale San Raffaele, Milan, Italy
Volpe A.:
Department of Urology, University of Eastern Piedmont, Maggiore della Carità Hospital, Novara, Italy
Brookman-May S.:
Ludwig-Maximilians University (LMU) Munich, Campus Grosshadern, Dept. of Urology, Janssen Pharma Research and Development, Los Angeles, CA, United States
Gschwend J.E.:
Department of Urology, Technical University of Munich, Rechts der Isar University Hospital, Munich, Germany
Smaldone M.C.:
Division of Urologic Oncology, Fox Chase Cancer Center, Philadelphia, United States
Uzzo R.G.:
Division of Urologic Oncology, Fox Chase Cancer Center, Philadelphia, United States
Carini M.:
Department of Urology, University of Florence, Florence, Italy, Department of Experimental and Clinical Medicine, University of Florence, Florence, Italy
Kutikov A.:
Division of Urologic Oncology, Fox Chase Cancer Center, Philadelphia, United States
Minervini A.:
Department of Urology, University of Florence, Florence, Italy, Department of Experimental and Clinical Medicine, University of Florence, Florence, Italy
|